OECD Home › Science and technology › Publications & Documents
Publications & Documents
Facilitating the mobilisation, sharing, or exchange of patents is important to promote innovation. Analysis of the functions, business models, and activities of IP specialist firms which organise the circulation of patented inventions is the central topic of this research.
The STI Scoreboard illustrates and analyses a wide set of indicators of science, technology, globalisation and industrial performance in OECD and major non-OECD countries. It includes the latest figures for R&D, foreign direct investment, risk capital and technology-related trade.
This paper investigates the characteristics, functioning and incidence of pre-emptive patenting, defined as patent filings whose main effect is to hamper the grant of other patents.
What impact has the crisis had on innovation and spending on research and development? How can innovation help to solve environmental and social threats? The OECD Science, Technology and Industry Scoreboard 2009 provides the data and analysis to answer these questions.
This country note, extracted from the STI Scoreboard 2009, explores recent developments in matters relating to innovation, science, technology and globalisation in the United States.
English, , 287kb
The aim of these guidelines is to propose a harmonised approach for the collection and analysis of biotechnology research and development (R&D) statistics in the government and higher education sectors.
This book throws a spotlight on innovation across the software universe, setting out key issues and highlighting policy perspectives. It spans research and development, invention, production, distribution and use of software in the market.
Following the recommendation from the ICCM2 (SAICM), OECD and UNITAR agreed to hold a series of “IOMC/OECD/UNITAR Awareness-Raising Workshops for Developing and Transition Countries on Nanotechnology /Manufactured Nanomaterials” in conjunction with SAICM regional meetings during 2009/2010
This book presents the main results of the first large-scale effort to exploit firm-level data from innovation surveys across 20 countries in an internationally harmonised way, with a view to addressing common analytical questions.
This book reviews how the emergence of pharmacogenetics will impact the efficiency of pharmaceutical R&D and improve healthcare decision making and clinical care. It discusses what policies need to change in order for the public to reap the benefits from advances in diagnostic genetic testin